Possis shareholder lawsuit dismissed
This article was originally published in The Gray Sheet
Executive Summary
U.S. Court of Appeals for the Eighth Circuit on March 24 affirms a previous decision by the U.S. District Court for the District of Minnesota to dismiss with prejudice a shareholder lawsuit filed June 5, 2005 against Minneapolis endovascular device firm Possis Medical and two of its executive officers. The suit had alleged the firm misrepresented material information about the company's AngioJet Rheolytic thrombectomy system prior to its August 2004 disclosure of results from its AiMI clinical trial, Possis said. Bayer HealthCare acquired Possis for $361 million in February (1"The Gray Sheet" Feb. 18, 2008, p. 10)
You may also be interested in...
Bayer Builds Cardiovascular Franchise With Possis Purchase
Bayer HealthCare will expand its cardiovascular device offerings by acquiring AngioJet thrombectomy system maker Possis Medical for $361 million under a deal announced Feb. 11
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.